By demonstrating that piperine suppresses the PI3K/Akt pathway and activates ERK signaling in ROS-dependent manners, our findings suggest that piperine could be particularly beneficial in CRC patients exhibiting an aberrant activation of these pathways. The gene discussed is AKT1; the disease is colorectal carcinoma.